Scientific publications

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

Oct 1, 2021 | Magazine: Neurología

E Caronna  1 , V José Gallardo  2 , A Alpuente  1 , M Torres-Ferrus  1 , N M Sánchez-Mateo  3 , J Viguera-Romero  4 , A C López-Veloso  5 , A López-Bravo  6 , A B Gago-Veiga  7 , P Irimia Sieira  8 , J Porta-Etessam  9 , S Santos-Lasaosa  10 , P Pozo-Rosich  11 , Spanish CGRP-COVID Study Group

Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus.

Methods: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms.

Results: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P=.320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment.

Conclusion: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.

CITATION  Neurologia. 2021 Oct;36(8):611-617.  doi: 10.1016/j.nrleng.2021.03.005.

Our authors